260 related articles for article (PubMed ID: 35175882)
1. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
[TBL] [Abstract][Full Text] [Related]
3. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
4. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
5. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
Lewis KD; Peris K; Sekulic A; Stratigos AJ; Dunn L; Eroglu Z; Chang ALS; Migden MR; Yoo SY; Mohan K; Coates E; Okoye E; Bowler T; Baurain JF; Bechter O; Hauschild A; Butler MO; Hernandez-Aya L; Licitra L; Neves RI; Ruiz ES; Seebach F; Lowy I; Goncalves P; Fury MG
Ann Oncol; 2024 Feb; 35(2):221-228. PubMed ID: 38072158
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
10. The current clinical approach to difficult-to-treat basal cell carcinomas.
Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
[TBL] [Abstract][Full Text] [Related]
12. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
14. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
15. Treatments on the horizon for locally advanced basal cell carcinoma.
Idriss MH; Stull CM; Migden MR
Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
Chen L; Aria AB; Silapunt S; Lee HH; Migden MR
Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
